Aims Rosuvastatin (10 mg per day) compared with placebo reduced major adverse
cardiovascular (CV) events by 24% in 12 705 participants at intermediate CV risk after 5.6 …

Prevention of coronary heart disease in clinical practice: recommendations of the task force
of the European Society of cardiology, European atherosclerosis Society and European …

Background and purpose Secondary prevention in ischaemic stroke and transient ischaemic
attack (TIA) is dominated by pharmacological interventions with evidence for non …

Objective: To determine secondary preventive treatment and habits among patients with
coronary heart disease in general practice. Design: Process of care data on a random …

Prevention of cardiovascular disease, undoubtedly an emphasis of clinical care in 2014, will
provide both opportunities and challenges to patients and their healthcare providers. The …

Background Lifestyle modification programmes for coronary heart disease patients have
been shown to effectively improve risk factors and related health behaviours, quality of life …

A “polypill” for the primary prevention of cardiovascular disease has been proposed. We
estimated the projected benefit of a secondary prevention “poly-portfolio” strategy, including …

Context Coronary heart disease (CHD) is responsible for about 15% of all deaths worldwide
and is identified as a top priority for decision makers. Both primary and secondary …

The decline in cardiovascular mortality in Europe by nearly 50% over the last three decades
resulted in particular from improved risk factor control and prevention interventions in …